Severe COVID-19 can trigger a cytokine storm, leading to acute respiratory distress syndrome (ARDS) with similarities to superantigen-induced toxic shock syndrome. An outstanding question is whether SARS-CoV-2 protein sequences can directly induce inflammatory responses. In this study, we identify a region in the SARS-CoV-2 S2 spike protein with sequence homology to bacterial super-antigens (termed P3). Computational modeling predicts P3 binding to sites on MHC class I/II and the TCR that partially overlap with sites for the binding of staphylococcal enterotoxins B and H. Like SEB and SEH derived peptides, P3 stimulated 25-40% of human CD4+ and CD8 + T-cells, increasing IFN-γ and granzyme B production. viSNE and SPADE profiling identified overlapping and distinct IFN-γ+ and GZMB+ subsets. The super-antigenic properties of P3 were further evident by its selective expansion of T-cells expressing specific TCR Vα and Vβ chain repertoires. In vivo experiments in mice revealed that the administration of P3 led to a significant upregulation of proinflammatory cytokines IL-1β, IL-6, and TNF-α. While the clinical significance of P3 in COVID-19 remains unclear, its homology to other mammalian proteins suggests a potential role for this peptide family in human inflammation and autoimmunity.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s42003-024-07350-8DOI Listing

Publication Analysis

Top Keywords

identification sars-cov2
4
sars-cov2 protein
4
protein derived
4
derived peptide
4
peptide super-antigen-like
4
super-antigen-like stimulatory
4
stimulatory properties
4
properties t-cells
4
t-cells severe
4
severe covid-19
4

Similar Publications

Severe COVID-19 can trigger a cytokine storm, leading to acute respiratory distress syndrome (ARDS) with similarities to superantigen-induced toxic shock syndrome. An outstanding question is whether SARS-CoV-2 protein sequences can directly induce inflammatory responses. In this study, we identify a region in the SARS-CoV-2 S2 spike protein with sequence homology to bacterial super-antigens (termed P3).

View Article and Find Full Text PDF

Severe COVID-19 can trigger a cytokine storm, leading to acute respiratory distress syndrome (ARDS) with similarities to superantigen-induced toxic shock syndrome. An outstanding question is whether SARS-CoV-2 protein sequences can directly induce inflammatory responses. In this study, we identify a region in the SARS-CoV-2 S2 spike protein with sequence homology to bacterial super-antigens (termed P3).

View Article and Find Full Text PDF
Article Synopsis
  • Coronaviruses can originate from animals and cause serious illnesses in both humans and animals, with a key protein called Mac1 playing a role in viral replication and interferon inhibition.
  • Researchers discovered a compound, MCD-628, that inhibits Mac1 but found its effectiveness was limited due to poor permeability.
  • By creating more hydrophobic derivatives, they identified four compounds that successfully inhibited Mac1 and reduced replication of coronaviruses, confirming their specificity through drug-resistance mutations, but this resistance came at a cost to the virus's overall fitness.
View Article and Find Full Text PDF

Identification of CRTH2 as a New PPARγ-Target Gene in T Cells Suggested CRTH2 Dependent Conversion of T2 Cells as Therapeutic Concept in COVID-19 Infection.

Immunotargets Ther

November 2024

Goethe University Frankfurt, Department of Anaesthesiology, Intensive Care Medicine, and Pain Therapy, University Hospital Frankfurt, Frankfurt, 60590, Germany.

Background: COVID-19 is a serious viral infection, which is often associated with a lethal outcome. Therefore, understanding mechanisms, which affect the immune response during SARS-CoV2 infection, are important.

Methods: To address this, we determined the number of T cells in peripheral blood derived from intensive care COVID-19 patients.

View Article and Find Full Text PDF

: In susceptible hosts, SARS-CoV2-induced hyperinflammation accounts for an increased mortality. The search of adjuvant immunomodulatory therapies has been ongoing ever since the pandemic outbreak. Aim: Our purpose was to evaluate the efficacy of cyclosporin A (CsA) as an add-on therapy to the standard of care (SoC) in patients with severe COVID-19 pneumonia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!